{"id":"atazanavir-2-nrtis","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia (unconjugated)"},{"rate":"5-10","effect":"Jaundice"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"1-2","effect":"Nephrolithiasis"},{"rate":"5-10","effect":"PR interval prolongation"}]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that binds to and blocks HIV protease, preventing the cleavage of viral polyproteins necessary for producing mature, infectious viral particles. The two NRTIs work synergistically by inhibiting reverse transcriptase, the enzyme that converts HIV RNA into DNA, thereby blocking an earlier step in viral replication. Together, this triple-drug combination provides potent suppression of HIV replication through complementary mechanisms.","oneSentence":"Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:46.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"HIV-1 infection as part of combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT01511809","phase":"PHASE3","title":"Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2010-09","conditions":"HIV-1 Infection","enrollment":117},{"nctId":"NCT00006604","phase":"PHASE1, PHASE2","title":"Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"HIV Infections","enrollment":195},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT00411957","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-01","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT02473328","phase":"PHASE2","title":"Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2015-06","conditions":"HIV-1 Infection","enrollment":90},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT01691794","phase":"PHASE4","title":"Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-11-30","conditions":"HIV, Pediatric","enrollment":108},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44},{"nctId":"NCT01814722","phase":"","title":"Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-09","conditions":"Human Immunodeficiency Virus","enrollment":63},{"nctId":"NCT01159223","phase":"PHASE4","title":"Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-05","conditions":"HIV Infections","enrollment":559},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01307488","phase":"PHASE4","title":"Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-09","conditions":"HIV Infection","enrollment":286},{"nctId":"NCT00885482","phase":"PHASE4","title":"Atazanavir and Lamivudine for Treatment Simplification","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2009-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00811954","phase":"PHASE3","title":"Comparative Study of Three NNRTI-Sparing HAART Regimens","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-05","conditions":"HIV Infection","enrollment":1814},{"nctId":"NCT01656109","phase":"PHASE2","title":"Atazavanir/Ritonavir-based HAART in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-07","conditions":"HIV","enrollment":20},{"nctId":"NCT00540137","phase":"PHASE4","title":"The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2007-07","conditions":"HIV Infections","enrollment":21},{"nctId":"NCT00896051","phase":"PHASE2","title":"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2009-08","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":50},{"nctId":"NCT01232127","phase":"PHASE4","title":"Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-02","conditions":"HIV","enrollment":25},{"nctId":"NCT00225017","phase":"PHASE3","title":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-06","conditions":"HIV Infection, Hyperlipidemia","enrollment":50},{"nctId":"NCT01445223","phase":"PHASE4","title":"A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2004-04","conditions":"HIV","enrollment":242},{"nctId":"NCT00028067","phase":"PHASE3","title":"A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2001-08","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00135356","phase":"PHASE4","title":"Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-07","conditions":"HIV-Associated Lipodystrophy Syndrome","enrollment":219},{"nctId":"NCT00120393","phase":"PHASE3","title":"Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-01","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00135395","phase":"PHASE3","title":"A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00207142","phase":"PHASE4","title":"Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"HIV Infections","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reyataz"],"phase":"marketed","status":"active","brandName":"Atazanavir + 2 NRTIs","genericName":"Atazanavir + 2 NRTIs","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}